Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134485 · ClinicalTrials.gov registry record · Phase 3
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
NCT00134485 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 400 participants.
The verdict
NCT00134485, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
Study Summary
The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia
Interventions
- DRUG atorvastatin
- DRUG torcetrapib/atorvastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2005-03 |
| Est. Completion | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00134485
The ClinicalTrials.gov registry entry for NCT00134485 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which atorvastatin is the first listed.
NCT00134485 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00134485 about?
NCT00134485 is a clinical study titled "Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia". The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia
What is the current status of trial NCT00134485?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2005-03. Estimated completion is 2006-03.
What interventions are being tested in trial NCT00134485?
The interventions under investigation include: atorvastatin (DRUG), torcetrapib/atorvastatin (DRUG).
Who is sponsoring clinical trial NCT00134485?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.